These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

474 related items for PubMed ID: 17625124

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Scott J, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M.
    Lancet; 2014 Aug 02; 384(9941):414-26. PubMed ID: 24907224
    [Abstract] [Full Text] [Related]

  • 3. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
    Marcellin P, Cooper C, Balart L, Larrey D, Box T, Yoshida E, Lawitz E, Buggisch P, Ferenci P, Weltman M, Labriola-Tompkins E, Le Pogam S, Nájera I, Thomas D, Hooper G, Shulman NS, Zhang Y, Navarro MT, Lim CY, Brunda M, Terrault NA, Yetzer ES.
    Gastroenterology; 2013 Oct 02; 145(4):790-800.e3. PubMed ID: 23811112
    [Abstract] [Full Text] [Related]

  • 4. Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.
    Reddy KR, Shiffman ML, Rodriguez-Torres M, Cheinquer H, Abdurakhmanov D, Bakulin I, Morozov V, Silva GF, Geyvandova N, Stanciu C, Rabbia M, McKenna M, Thommes JA, Harrison SA, PROGRESS Study Investigators.
    Gastroenterology; 2010 Dec 02; 139(6):1972-83. PubMed ID: 20816836
    [Abstract] [Full Text] [Related]

  • 5. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
    Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S, PROVE2 Study Team.
    N Engl J Med; 2009 Apr 30; 360(18):1839-50. PubMed ID: 19403903
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT, APRICOT Study Group.
    N Engl J Med; 2004 Jul 29; 351(5):438-50. PubMed ID: 15282351
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.
    von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, Bergk A, Bernsmeier C, Häussinger D, Herrmann E, Zeuzem S.
    Gastroenterology; 2005 Aug 29; 129(2):522-7. PubMed ID: 16083709
    [Abstract] [Full Text] [Related]

  • 15. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J.
    N Engl J Med; 2002 Sep 26; 347(13):975-82. PubMed ID: 12324553
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial.
    Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta V, Vinelli F, Scotto G, Montalto G, Romano M, Cristofaro G, Mottola L, Spirito F, Andriulli A.
    Hepatology; 2008 Jan 26; 47(1):43-50. PubMed ID: 18069698
    [Abstract] [Full Text] [Related]

  • 18. Telaprevir for retreatment of HCV infection.
    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M, REALIZE Study Team.
    N Engl J Med; 2011 Jun 23; 364(25):2417-28. PubMed ID: 21696308
    [Abstract] [Full Text] [Related]

  • 19. Sofosbuvir for previously untreated chronic hepatitis C infection.
    Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ.
    N Engl J Med; 2013 May 16; 368(20):1878-87. PubMed ID: 23607594
    [Abstract] [Full Text] [Related]

  • 20. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
    McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ, PROVE1 Study Team.
    N Engl J Med; 2009 Apr 30; 360(18):1827-38. PubMed ID: 19403902
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.